Adage Capital Partners Gp, L.L.C. Syndax Pharmaceuticals Inc Transaction History
Adage Capital Partners Gp, L.L.C.
- $51.6 Billion
- Q1 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 631,640 shares of SNDX stock, worth $7.05 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
631,640
Previous 621,840
1.58%
Holding current value
$7.05 Million
Previous $8.22 Million
5.57%
% of portfolio
0.02%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding SNDX
# of Institutions
240Shares Held
101MCall Options Held
1.36MPut Options Held
618K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$95.1 Million8.82% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$88.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.87MShares$54.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.21MShares$47 Million5.73% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.01MShares$44.7 Million0.12% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $631M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...